The effectiveness of FloSealA (R) matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study

The objective of this study was to compare the effectiveness of FloSealA (R) matrix hemostatic agent with hemostatic surgical procedures and TabotampA (R) in thyroid surgery. One hundred fifty-five consecutive total thyroidectomy patients were recruited at our institution between January 2005 and December 2007. Exclusion criteria were applied. Patients were randomized to one of three hemostatic approaches: 49 received surgical procedures only, and 52 received oxidized regenerated cellulose patch (Tabotamp Fibrillar 2.5 x 5 cm) and 54 FloSeal (5,000 U/5 mL). The same surgeon performed all operations. Mean operating time was reduced in the FloSeal group (105 min) vs. surgical (133 min, p = 0.02) and vs. Tabotamp (122 min, p = 0.0003). Also, wound drain removal occurred earlier with FloSeal (p = 0.006 vs. surgical; p = 0.008 vs. Tabotamp) resulting in shorter postoperative hospital stay in the FloSeal group (p = 0.02 vs. surgical; p = 0.002 vs. Tabotamp). FloSeal matrix is an effective additional agent to conventional haemostatic procedures in thyroid surgery.